TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

Benzinga Logo Benzinga By Business Wire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against MoonLake Immunotherapeutics for allegedly making false and misleading statements about its drug candidate sonelokimab, which led to a significant stock price drop after disappointing Phase 3 trial results.

Insights
AMAT   neutral

Reporting Q4 results with no explicit positive or negative pre-announcement signals


MLTX   negative

The company is accused of misleading investors about its drug candidate's effectiveness, resulting in a nearly 90% stock value loss and potential legal action